The Global Fund, PEPFAR, CIFF, and BMGF are collaborating to provide affordable access to lenacapavir for HIV prevention, aiming to reach at least 2 million people in three years. Gilead Sciences’ lenacapavir is showing promise in preventing new HIV infections and has been licensed for manufacturing in low- and lower-middle-income countries. The goal is to accelerate progress towards ending HIV/AIDS as a public health threat by 2030 through widespread access to this innovative treatment.
Full Article
Sudan ‘pathway to peace’ talks in London bring together EU, UK and AU
A high-level international conference in London, hosted by UK Foreign Secretary David Lammy, aims to find "a pathway to peace" in Sudan, where a civil war has caused the world's worst humanitarian crisis. The UK pledges an additional $120 million in assistance as 30 million people face starvation, with reports of widespread violence and displacement. The African Union emphasizes the need for an immediate ceasefire and inclusive dialogue, while the main warring parties are excluded...
Read more